Clinical Trial Search

Primary: Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining — 1.62 % of strongly/moderately stained nuclei — p=0.54

Primary: Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997). The CY-BOCS is a 10-item Semi-structured Measure of Obsession and Compulsion Severity…

Primary: Progression Free Survival — 7.8; 2.8; 10.9 months — p=.08

Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants

Primary: Verification of the Automation and Telemetry Components — 16.5 failures

Primary: Quadriceps Muscle Force — 1.27; 1.37; 0.79; 0.66 Nm/kg — p=0.07

Primary: Cell Proliferation in the Prostatectomy Tissue as Assessed by Ki67 Expression Using Immunohistochemistry (IHC) — 6.5; 3.67 % positively stained nuclei — p=0.23

Primary: Change From Baseline in Faces Pain Scale Revised (FPS-R) at 30 Minutes After IV Cannulation — -3.544; -3.436 units on a scale

Primary: Change From Unified Parkinson´s Disease Rating Scale - UPDRS — 24; 30; 21.2; 21.8 units on a scale

Primary: Overall Response Rate — 0.029 proportion of paticipants

Primary: Disease-free Survival — NA; 55.1 months

Primary: Mean Change in International Prostate Symptom Score (IPSS) — -4.46; -5.65; -6.11; -5.88 percentage change from baseline — p=0.0911

Primary: Percentage of Subjects With Best Overall Confirmed Response Rate (BORR) — 54.5; 61.2 Percentage of subjects

Primary: The Primary Efficacy Endpoint of This Study is the Best Overall Response (Complete Response + Partial Response) — 61.76; 68.42 percentage of Best overall Response

Primary: Maximum Tolerated Dose of Vorinostat, Defined as the Dose at Which Fewer Than One-third of Patients Experience DLTs, Graded According to NCI CTCAE (Common Toxicity…